非诺贝特与血脂康治疗高脂血症的疗效分析

The Observation of Fenofibrate and Xuezhikang Treating Hyperlipidemia

目的探讨非诺贝特和血脂康治疗高脂血症的临床疗效。方法将随机抽取2013年6—10月该院收治的70例患有高脂血症的患者随机分为A.B两组,A组治疗组35例予以非诺贝特治疗,B组对照组35例予以血脂康治疗,A、B两组均治疗12周后,观察A.B两组患者的血液生化指标的改变。结果两组治疗前血液生化指标差异无统计学意义(P>0.05)。非诺贝特和血脂康在治疗高脂血症12周后的患者的血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)均有改善(P<0.05),但A组改善情况明显优于B组,差异有统计学意义(P<0.05)。结论非诺贝特和血脂康均有调脂作用,血脂康调脂作用缓和,疗效缓慢。非诺贝特治疗高脂血症疗效显著,作用确切,为临床用药提供参考。

Objective To evaluate the clinical efficacy of fenofibrate and Xuezhikang treating hyperlipidemia. Methods 70 patients with hyperlipidemia were randomly divided into two groups AB, A group of 35 people to be treated fenofibrate therapy, group B group of 35 people to be Xuezhikang, after 16 weeks of treatment, observation AB changes in the two groups were blood biochemical indices. Results Before treatment, blood biochemical parameters showed no significant difference(P> 0.05). Fenofibrate and Xuezhikang blood indices in patients after 16 weeks of treatment of hyperlipidemia have changed, and a marked improvement in group A than group B, the difference was statistically significant(P <0.05). Conclusion fenofibrate in treating hyperlipidemia in a significant effect, worthy of promotion.